Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Sernova Corp.TSX: SVA.TO

Gross Profit · Q2 FY2026 · quarter ended Apr 2026

Gross profit remains negative

Q2 FY2026 gross profit was -CA$4.43K, compared with -CA$47.66K a year earlier. Trailing-twelve-month gross profit was -CA$256.13K.

Context

  • Gross profit grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -CA$4.43K or moves back toward the trailing-twelve-month quarterly average of -CA$64.03K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
-CA$4.43K+0.0% QoQ
Last fiscal yearOct 2025
-CA$342.59K+36.6% YoY
LTMApr 2026
-CA$256.13K+40.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+90.7%——
1 year+36.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
(342.59K) CAD
Year-over-year change
+36.6%

Gross Profit vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +40.2% is the lowest of 2, against a peer median of +62.8%.
SVA.TO Competitors
Gross Profit for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026-$26.59K USD+62.8%——
SVA.TOSernova Corp.LTM Apr 2026-CA$256.13K CAD+40.2%——
Peer median (excluding SVA.TO) —+62.8%——

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue267.2K440K445.55K540.28K342.59K
Gross Profit(267.2K)(440K)(445.55K)(540.28K)(342.59K)
Gross Margin—————
Research & Development4.64M16.9M32.26M22.36M7.28M
Selling, General & Admin2.29M7.83M8.46M8.97M7.5M
Operating Expenses6.94M24.75M41.13M31.84M14.78M
Depreciation & Amortization267.2K440K308.49K410.53K342.59K
EBITDA(6.6M)(24.54M)(40.19M)(31.25M)(14.74M)
EBITDA Margin—————
Operating Income(6.87M)(24.18M)(41.13M)(31.84M)(15.12M)
Operating Margin—————
Interest Income70.55K577.29K1.5M388.39K25.63K
Interest Expense58.37K118K32.08K586.86K754.81K
Other Income / Expenses1.09M1.01M1.5M(347.04K)(711.01K)
Income Before Tax(6.97M)(24.42M)(39.63M)(32.19M)(15.84M)
Pre-Tax Margin—————
Income Tax Expense58.37K118K(629.02K)7K(92.19K)
Net Income(7.02M)(24.54M)(39M)(32.19M)(15.74M)
Net Margin—————
EPS (Basic)(0.03)(0.09)(0.13)(0.10)(0.05)
EPS (Diluted)(0.03)(0.09)(0.13)(0.10)(0.05)
Weighted Avg Shares245.52M273.59M303.33M306.96M328.29M
Weighted Avg Shares (Diluted)245.52M273.59M303.33M306.95M328.29M

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.